The digital healthcare platform aims to create an end-to-end patient journey from diagnostic results to prescription and fulfilment.
Norfolk-based NHS-licensed digital healthcare platform Evaro has partnered with U-Test Diagnostics, a provider of rapid home testing kits, to become the first company of its kind in the UK to offer customers a pathway from diagnostic results to prescription and fulfilment.
The integration comes as home testing adoption accelerates post-pandemic. A 2024 parliamentary report found that routine COVID-19 testing “added to the general public’s comfort with self-testing, increasing the acceptability of, and demand for, self-tests more broadly”.
“People are already comfortable testing themselves at home,” said Thuria Wenbar, chief executive and co-founder of Evaro.
“The next stage of that experience is discrete, safe, immediate access to treatment. By connecting U-Test Diagnostics’ diagnostic capability with our NHS-licensed prescribing infrastructure, we’re creating the kind of end-to-end patient journey that I’m hoping will become standard in 2026. I’ve said it before, and I’ll say it again: healthcare should be as universal and accessible as online banking,” she added.
Online consultations
The partnership benefits from Evaro’s asynchronous consultation model, which requires no appointments or video calls. Patients complete discrete online consultations reviewed by NHS-registered clinicians, with treatments dispensed and delivered the next day in most cases. Evaro has held comprehensive regulatory credentials, including CQC and GPhC licenses since 2018, with NHS integration enabling GP record access for safer prescribing.
For U-Test Diagnostics, the partnership deepens customer relationships while creating a new revenue stream with minimal technical implementation. U-Test Diagnostics supplies rapid home testing kits. With over 15 years of industry experience, the Welsh company has supplied more than 75 million lateral flow testing kits over the last five years to medical organisations, government bodies, and major corporations, including Ford Motors and Mercedes-Benz across the UK, Australia, the US and Europe.
“U-Test Diagnostics has always been focused on making reliable testing more accessible and convenient for everyone,” said the firm’s co-founder and managing director Harry Griffiths.
“Partnering with Evaro helps us bridge the gap between home testing and treatment, giving customers a seamless pathway from results to prescription and fulfilment, without the usual delays,” he added.
Last month, Evaro closed $25 million (£18.1 million) Series A funding to help scale its healthcare-as-a-service model. The round was led by AlbionVC, the technology investment arm of Albion Capital Group, with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI.
link